NASDAQ:VRDN Viridian Therapeutics (VRDN) Stock Price, News & Analysis $23.28 +0.23 (+1.00%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Viridian Therapeutics Stock (NASDAQ:VRDN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Viridian Therapeutics alerts:Sign Up Key Stats Today's Range$23.25▼$24.0050-Day Range$13.47▼$24.9852-Week Range$11.40▼$25.39Volume525,166 shsAverage Volume1.11 million shsMarket Capitalization$1.49 billionP/E RatioN/ADividend YieldN/APrice Target$35.80Consensus RatingModerate Buy Company OverviewViridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.Read More… Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Viridian Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks57th Percentile Overall ScoreVRDN MarketRank™: Viridian Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 484th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingViridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageViridian Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Viridian Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Viridian Therapeutics are expected to decrease in the coming year, from ($3.94) to ($4.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viridian Therapeutics is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viridian Therapeutics is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViridian Therapeutics has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Viridian Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.32% of the outstanding shares of Viridian Therapeutics have been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Viridian Therapeutics has recently decreased by 3.55%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldViridian Therapeutics does not currently pay a dividend.Dividend GrowthViridian Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.32% of the outstanding shares of Viridian Therapeutics have been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Viridian Therapeutics has recently decreased by 3.55%, indicating that investor sentiment is improving. News and Social Media2.1 / 5News Sentiment0.74 News SentimentViridian Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Viridian Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for VRDN on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -88% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Viridian Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $30,616,312.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.65% of the stock of Viridian Therapeutics is held by insiders.Read more about Viridian Therapeutics' insider trading history. Receive VRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VRDN Stock News HeadlinesViridian Therapeutics, Inc. (NASDAQ:VRDN) COO Purchases $117,050.00 in StockOctober 1, 2024 | insidertrades.comBuy Rating for Viridian Therapeutics Boosted by Promising VRDN-001 Trial Results and Pipeline PotentialOctober 28 at 10:59 PM | markets.businessinsider.comElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 29, 2024 | Porter & Company (Ad)Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of "Moderate Buy" by AnalystsOctober 26 at 2:27 AM | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Stock Quotes, Forecast and News SummaryOctober 24, 2024 | benzinga.comViridian Therapeutics (VRDN): A Small-Cap Biotech with Promising Clinical ResultsOctober 24, 2024 | msn.comViridian Therapeutics' Superior Prospects Make It A BuyOctober 23, 2024 | seekingalpha.comViridian Therapeutics’ FcRn Inhibitor Potential and Upcoming Data Catalysts Drive Buy RatingOctober 22, 2024 | markets.businessinsider.comSee More Headlines VRDN Stock Analysis - Frequently Asked Questions How have VRDN shares performed this year? Viridian Therapeutics' stock was trading at $21.78 at the beginning of 2024. Since then, VRDN shares have increased by 6.9% and is now trading at $23.28. View the best growth stocks for 2024 here. How were Viridian Therapeutics' earnings last quarter? Viridian Therapeutics, Inc. (NASDAQ:VRDN) released its quarterly earnings results on Thursday, August, 8th. The company reported ($1.02) EPS for the quarter, missing analysts' consensus estimates of ($0.87) by $0.15. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.09 million. Viridian Therapeutics had a negative net margin of 79,185.77% and a negative trailing twelve-month return on equity of 83.18%. Who are Viridian Therapeutics' major shareholders? Top institutional shareholders of Viridian Therapeutics include Novo Holdings A S (3.73%), Hennion & Walsh Asset Management Inc. (0.31%), International Assets Investment Management LLC (0.03%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Fairmount Funds Management Llc, Jonathan Violin, Scott Dunseth Myers, Lara Meisner, Stephen F Mahoney, Thomas W Beetham and Barrett Katz. View institutional ownership trends. How do I buy shares of Viridian Therapeutics? Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Viridian Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Viridian Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/08/2024Today10/28/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:VRDN CUSIPN/A CIK1590750 Webwww.viridiantherapeutics.com Phone(617) 272-4600Fax760-537-4101Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$35.80 High Stock Price Target$61.00 Low Stock Price Target$20.00 Potential Upside/Downside+53.8%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($4.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-237,730,000.00 Net Margins-79,185.77% Pretax Margin-79,185.77% Return on Equity-83.18% Return on Assets-44.82% Debt Debt-to-Equity Ratio0.05 Current Ratio15.82 Quick Ratio15.82 Sales & Book Value Annual Sales$310,000.00 Price / Sales4,797.93 Cash FlowN/A Price / Cash FlowN/A Book Value$4.48 per share Price / Book5.20Miscellaneous Outstanding Shares63,890,000Free Float63,475,000Market Cap$1.49 billion OptionableOptionable Beta1.08 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:VRDN) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.